https://www.selleckchem.com/pr....oducts/zebularine.ht
Burden of monogenic disease in transplant patients with ESKD of any cause prior to the age of 50 is between 21 and 51%. Early genetic testing can provide a non-invasive diagnostic, impacting prognostication and treatment and obviating the need for an invasive biopsy. We conclude that in patients who one expects to develop ESKD prior to the age of 50, genetic testing should be considered as first mode of diagnostics. Burden of monogenic disease in transplant patients with ESKD of any cause prior to the age of 50 is between 21 and 51%.
Like
Comment
Share
